Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

  |  

This study showed that RA patients with an inadequate response to conventional DMARDs, including methotrexate, may obtain significant clinical improvement with baricitinib.

Baricitinib has already been submitted for regulatory review in the U.S.2 Baricitinib (Olumiant) was granted marketing authorization in Europe by the European Commission in 2 mg and 4 mg film-coated tablets to treat moderate to severe active RA in adults who have had an inadequate response to, or who are intolerant to, one or more DMARDs.3

ADVERTISEMENT
SCROLL TO CONTINUE

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ADVERTISEMENT
SCROLL TO CONTINUE
  1. Taylor PC, Keystone EC, van der Heidje D, et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376:652–662. doi: 10.1056/NEJMoa1608345
  2. Eli Lilly and Co. News release: Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adalimumab and placebo. 2017 Feb 15.
  3. Eli Lilly and Co. News release: European commission approves once-daily Olumiant tablets for treatment of adults with moderate to severe active rheumatoid arthritis. 2017 Feb 13.

Related Articles

    Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

    Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

    Rheumatology Drugs at a Glance, Part 3: Rheumatoid Arthritis

    Over the past few years, bio­similars and other new drugs have been introduced to treat rheumatic illnesses. Some of the conditions we treat have numerous drug options, others have few or only off-label options. This series, “Rheumatology Drugs at a Glance,” provides streamlined information on the administration of biologic, biosimilar and small molecule inhibitor drugs…

    The Rescue: Moving RA Patients from Adalimumab to Baricitinib

    The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…

    New Insights & Approvals for Baricitinib

    New research shows that baricitinib is a safe and effective RA treatment. The medication has also been approved for use in Japan and is recommended for use in the U.K…